[1]金 蕊,何卫才,郭甲民,等.培元化瘀解毒方联合新辅助化疗治疗胃癌临床观察[J].陕西中医,2023,(9):1227-1230.[doi:DOI:10.3969/j.issn.1000-7369.2023.09.016]
 JIN Rui,HE Weicai,GUO Jiamin,et al.Clinical observation on Peiyuan Huayu Jiedu formula combined with neoadjuvant chemotherapy in patients with gastric cancer[J].,2023,(9):1227-1230.[doi:DOI:10.3969/j.issn.1000-7369.2023.09.016]
点击复制

培元化瘀解毒方联合新辅助化疗治疗胃癌临床观察
分享到:

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年9期
页码:
1227-1230
栏目:
临床研究
出版日期:
2023-09-05

文章信息/Info

Title:
Clinical observation on Peiyuan Huayu Jiedu formula combined with neoadjuvant chemotherapy in patients with gastric cancer
作者:
金 蕊1何卫才1郭甲民2王颖栋2马龙安2袁 彬3雎 岩3陈晓泉3赵培西1
(1.陕西省肿瘤医院药学部,陕西 西安 710061; 2.陕西省肿瘤医院普外科,陕西 西安 710061; 3.陕西省肿瘤医院中西医结合科,陕西 西安 710061)
Author(s):
JIN RuiHE WeicaiGUO JiaminWANG YingdongMA LonganYUAN BinJU YanCHEN XiaoquanZHAO Peixi
(Department of Pharmacy,Shaanxi Cancer Hospital,Xi'an 710061,China)
关键词:
胃癌 培元化瘀解毒方 新辅助化疗 对照研究 证候 抗肿瘤
Keywords:
Gastric cancer Peiyuan Huayu Jiedu formula Neoadjuvant chemotherapy Control study Symptoms Anti-tumor
分类号:
R 735.2
DOI:
DOI:10.3969/j.issn.1000-7369.2023.09.016
文献标志码:
A
摘要:
目的:开展培元化瘀解毒方联合新辅助化疗治疗进展期胃癌患者的对照研究,探究培元化瘀解毒方的临床疗效及安全性。方法:采用真实世界研究方法,尊重患者意愿,将纳入的64例进展期胃癌患者分为对照组和中西医联合组各32例。对照组给予奥沙利铂和替吉奥联合的SOX术前新辅助化疗方案; 中西医联合组在化疗基础上联合使用培元化瘀解毒方; 两组完成新辅助化疗后行胃癌手术。比较两组患者肿瘤退缩分级、疗效评价、中医证候积分、功能状态KPS评分、肿瘤标志物、血细胞计数及肝肾功能。结果:治疗后,与对照组相比,中西医联合组肿瘤退缩分级有效率更高(P<0.05)。中医证候方面,中西医联合组治疗前后的胃痛、腹胀、食少、呕吐、便溏、乏力评分,差异有统计学意义(P<0.05)。中西医联合组治疗后中医证候总积分和功能状态KPS评分明显改善,优于对照组(P<0.05)。而近期疗效、肿瘤标志物、血常规和生化等指标,两组治疗前后均无统计学差异(P>0.05)。结论:培元化瘀解毒方配合新辅助化疗可提高胃癌患者的肿瘤退缩分级,改善患者功能状态评分,提升生活质量,减轻细胞毒药物化疗的不良反应,对进展期胃癌患者起到协同抗肿瘤作用。
Abstract:
Objective:To conduct a controlled study on the combination of Peiyuan Huayu Jiedu formula and neoadjuvant chemotherapy in the treatment of advanced gastric cancer patients,explore the clinical efficacy and safety of Peiyuan Huayu Jiedu formula.Methods:64 patients with advanced gastric cancer were divided into a control group and a combination of traditional Chinese and western medicine group,with 32 patients in each group.The control group was treated with the combination of platinum and fluorouracil.The combination of traditional Chinese and Western medicine group uses the Peiyuan Huayu Jiedu formula on the basis of chemotherapy.Two groups underwent gastric cancer surgery after completing neoadjuvant chemotherapy.Compare the tumor regression grading,efficacy evaluation,traditional Chinese medicine syndrome score,functional status KPS score,tumor markers,blood cell count,and liver and kidney function between two groups of patients.Results:After treatment,compared with the control group,the combined Chinese and Western medicine group had a higher effective rate in tumor regression grading(P<0.05).In terms of traditional Chinese medicine syndromes,there was a statistically significant difference(P<0.05)in the scores of stomach pain,bloating,lack of appetite,vomiting,loose stools,and fatigue before and after treatment in the combined group of traditional Chinese and western medicine.After treatment with the combination of traditional Chinese and Western medicine,the total score of traditional Chinese medicine syndromes and the KPS score of functional status were significantly improved(P<0.05).However,there was no significant difference in recent efficacy,tumor markers,blood routine and biochemical indicators between the two groups before and after treatment(P>0.05).Conclusion:Peiyuan Huayu Jiedu formula combined with neoadjuvant chemotherapy can improve the tumor regression grade of gastric cancer patients,improve their functional status KPS score,improve their quality of life,alleviate the adverse reactions of cytotoxic drug chemotherapy,and have a synergistic anti-tumor effect on advanced gastric cancer patients.

参考文献/References:

[1] Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[2] Allemani C,Matsuda T.Global surveillance of trends in cancer survival 2000-14(CONCORD-3):Analysis of individual records for 37-513-025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J].Lancet,2018,391(10125):1023-1075.
[3] 中华人民共和国国家卫生健康委员会医政医管局.胃癌诊疗指南(2022年版)[J].中华消化外科杂志,2022,21(9):1137-1164.
[4] 赫 捷,陈万青,李兆申,等,中国胃癌筛查与早诊早治指南制定专家组,中国胃癌筛查与早诊早治指南制定工作组.中国胃癌筛查与早诊早治指南(2022,北京)[J].中华肿瘤杂志,2022,44(7):634-666.
[5] 石颖鹏,王敏娟,李程亮.肠化生相关分子与胃癌的发生和进展研究概况[J].陕西医学杂志,2019,48(7):958-961.
[6] 中国抗癌协会胃癌专业委员会.局部进展期胃癌围手术期治疗中国专家共识(2021版)[J].中华胃肠外科杂志,2021,24(9):741-748.
[7] 靳祎祎,林久茂.中医药对肿瘤化疗药物增效减毒作用的研究进展[J].福建中医药,2019,50(1):85-88.
[8] 林 慧,梅全喜.中医药联合化疗抗肿瘤增效减毒实验与临床研究综述[J].亚太传统医药,2022,18(2):230-233.
[9] 任素娟,周 瑞,唐志书,等.中医药辅助放疗与化疗减毒增效研究进展[J].中华中医药杂志,2022,37(12):7233-7239.
[10] 赵培西,许建秦,袁 彬,等.扶正抗癌方治疗肝癌肝郁脾虚瘀毒证临床研究[J].陕西中医,2022,43(12):1746-1748.
[11] 王一乔,高 宏,邢向荣.中医药对于晚期实体肿瘤抗血管靶向药减毒增效作用的回顾性研究[J].实用中医内科杂志,2022,35(11):1-6.
[12] 周 蓓,梁艳菊.周岱翰教授病证症结合辨治原发性肝癌经验简介[J].新中医,2011,53(8):185-186.
[13] 赵红玉,杨 杰,王伶改,等.《伤寒论》中“病-证-症”结合的量化思维探析[J].中华中医药杂志,2020,35(9):4578-4580.
[14] 宋 卓,苏春雨,徐竞男,等.扶正解毒法防治胃癌的理论基础及循证依据[J].中医杂志,2016,57(10):829-833.
[15] 李朝燕,赵爱光,徐 燕,等.健脾中药联合奥铂及氟尿嘧啶类药物化疗对晚期胃癌患者预后的影响[J].世界科学技术-中医药现代化,2019,21(7):1372-1377.
[16] 奚肇宏,夏军权,滑永志,等.益气健脾法治疗脾胃虚弱型青年慢性萎缩性胃炎的疗效观察[J].中国中西医结合消化杂志,2020,28(1):8-11.
[17] 李 阳,王院春,王希胜,等.王希胜运用扶、化、固、调法辨治恶性肿瘤的经验[J].中医杂志,2019,60(19):1638-1642.
[18] 刘 贺.奥沙利铂联合氟尿嘧啶类药物治疗胃肠道恶性肿瘤患者所致的严重不良反应的回顾性分析[D].沈阳:中国医科大学,2021.
[19] 王雅楠,归明彬,屈莲平,等.黄芪多糖抑制结肠癌肿瘤微环境IDO1的表达增加瘤内CD8+ T细胞浸润[J].中国中药杂志,2023,48(5):1-10.
[20] 刘豪杰,陈雪蕾,包萨如拉.白花蛇舌草-半枝莲药对乙酸乙酯组分对胃癌SGC-7901细胞周期的影响[J].中医学报,2022,37(10):2198-2204.

相似文献/References:

[1]裴俊文,孙太振△,蒋立峰.基于对SGC7901细胞Survivin、Bcl2基因的调控 探讨益气化瘀散结方影响胃癌细胞增殖凋亡的作用机制*[J].陕西中医,2019,(4):411.
 PEI Junwen,SUN Taizhen,JIANG Lifeng..Study on the effect of Yiqi Huayu Sanjie decoction on the proliferation and apoptosis of gastric cancer cells based on the regulation of survivin and Bcl2 gene in SGC7901 cells[J].,2019,(9):411.
[2]高聪聪,范 筱,李 宁.益气健脾化积方对胃癌化疗疗效、患者安全性及预后影响的研究*[J].陕西中医,2019,(4):475.
[3]杨国强,闫强△.健脾解毒汤结合射频消融术治疗胃癌肝转移疗效研究[J].陕西中医,2019,(11):1510.
 YANG Guoqiang,YAN Qiang..Therapeutic effect of Jianpi Jiedu decoction combined with radiofrequency ablation on liver metastases from gastric cancer[J].,2019,(9):1510.
[4]马 婷,王品昊,朱 婕,等.行健汤联合穴位贴敷治疗进展期胃癌癌因性疲乏疗效及对患者免疫功能的影响*[J].陕西中医,2020,(10):1410.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.019]
[5]宋成鑫,葛信国△,储 晶.养阴健脾散毒法辅助化疗治疗晚期胃癌临床研究*[J].陕西中医,2020,(11):1543.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.007]
 SONG Chengxin,GE Xinguo,CHU Jing..Advanced gastric cancer treated by the method of nourishing Yin and invigorating spleen and dispersing toxin[J].,2020,(9):1543.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.007]
[6]周 锐,马灏川,陈亚栋,等.针灸辅助治疗胃癌现状及展望[J].陕西中医,2021,(8):1150.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.040]
 ZHOU Rui,MA Haochuan,CHEN Yadong,et al.Review of acupuncture and moxibusition on gastric cancer[J].,2021,(9):1150.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.040]
[7]孟 肖,张新庆,李 璐,等.培元益气汤改善气阴两虚证胃癌相关癌性疲乏及对患者免疫功能的影响[J].陕西中医,2023,(2):174.[doi:DOI:10.3969/j.issn.1000-7369.2023.02.008]
 MENG Xiao,ZHANG Xinqing,LI Lu,et al.Peiyuan Yiqi decoction improves cancer-related fatigue of gastric cancer with deficiency of qi and yin and its effect on immune function[J].,2023,(9):174.[doi:DOI:10.3969/j.issn.1000-7369.2023.02.008]
[8]苏园园,刘宁宁,赖优莹,等.胃癌中医证型研究进展[J].陕西中医,2023,(2):262.[doi:DOI:10.3969/j.issn.1000-7369.2023.02.029]
 SU Yuanyuan,LIU Ningning,LAI Youying,et al.Progress in traditional Chinese medicine syndrome types research of gastric cancer[J].,2023,(9):262.[doi:DOI:10.3969/j.issn.1000-7369.2023.02.029]
[9]李琳婵,鱼麦侠,郝梅梅,等.调中化湿汤对胃癌小鼠炎症损伤干预机制[J].陕西中医,2023,(3):294.[doi:DOI:10.3969/j.issn.1000-7369.2023.03.005]
[10]熊 婷,薛川松,颜 晔.益气养血汤联合参芪扶正注射液治疗胃癌患者肿瘤相关性贫血疗效研究[J].陕西中医,2023,(8):1065.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.015]
 XIONG Ting,XUE Chuansong,YAN Ye.Effect of Yiqi Yangxue decoction combined with Shenqi Fuzheng injection on cancer related anemia in patients with gastric cancer[J].,2023,(9):1065.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.015]

备注/Memo

备注/Memo:
基金项目:陕西省中医药管理局中医药传承创新暨秦药开发项目(2021-01-ZZ-012)
更新日期/Last Update: 2023-09-08